Auven Therapeutics is a global private equity firm that acquires and invests in proprietary therapeutic product candidates (small-molecules and biologics), and complementary technologies that address important unmet medical needs. Auven Therapeutics pursues an investment model of acquiring and developing mid-stage pharmaceutical programs to market approval or other value-inflection points. It aims to sell the successful products to companies with the relevant commercial infrastructure to market and sell the product worldwide.
Auven Therapeutics seeks to partner with biotechnology and pharmaceutical companies, contract research organizations (CROs), academic institutions and other appropriate healthcare organizations to bring valuable life-saving and quality of life-enhancing biomedical products to the global marketplace.
The General Partners of Auven Therapeutics are Stephen Evans-Freke and Dr. Peter B. Corr, who draw from a combined total of over 55 years across various sectors of the biomedical enterprise.
More information regarding Auven Therapeutics can be found at: www.auventherapeutics.com.